Search - tctmd.com

Displaying 1 - 9 of 9

Sort: Relevancy | Date

Presentation TCT 2018

RESET: Seven-Year Follow-up From a Randomized Trial of Sirolimus-Eluting vs Everolimus-Eluting Stents in Patients With Coronary Artery Disease

Presenter: James B. Hermiller Jr, Hiroki Shiomi

September 25, 2018

News Conference News TCT 2018

TALENT: Indian-Made Supraflex DES Stands Up Well Against Xience in All-Comers

Todd Neale

September 22, 2018

Polymer-Free BioFreedom Stent as Safe as Orsiro, but Not as Effective

News Conference News TCT 2018

CORRECTION: Polymer-Free BioFreedom Stent Faces Off Against Orsiro

Michael O'Riordan

September 22, 2018

News Opinion Editor's Corner TCT 2018

TCT 2018, Day One: ‘Back to the Future’ With Stents, Stents, and More Stents

Shelley Wood

September 22, 2018

Presentation TCT 2018

TCT-91: Ultrathin Bioresorbable Polymer Sirolimus-Eluting Stents versus Thin Durable Polymer Everolimus-Eluting Stents in Patients Undergoing Coronary Revascularization (BIOFLOW V): Acute Coronary Syndrome Subgroup Analysis

Presenter: Alexandre Abizaid, Didier Carrié, Ariel Roguin

September 21, 2018

Presentation TCT 2018

TCT-90: Clinical Outcomes Three Year After Revascularization With a Biodegradable Polymer Ultra-thin Strut Sirolimus-Eluting Stent and a Biodegradable Polymer Biolimus-eluting Stent. From the SORT OUT VII Trial

Presenter: Alexandre Abizaid, Didier Carrié, Julia Ellert

September 21, 2018

Presentation TCT 2018

TCT-197: Early Vascular Healing After Implantation of a Biolimus-Coated BioFreedom Stent or a Sirolimus Eluting Orsiro Stent in Patients with ST-segment Elevation Myocardial Infarction

Presenter: Alexandre Abizaid, Didier Carrié, Kirstine Hansen

September 21, 2018

Presentation TCT 2018

TCT-64: Two-Year Clinical and Imaging Outcomes of Thin Strut Sirolimus-Eluting Bioresorbable Vascular Scaffolds in De Novo Coronary Artery Lesions: The MeRes-1 Trial

Presenter: Antonio L. Bartorelli, David G. Rizik, Ricardo A. Costa

September 21, 2018

Presentation TCT 2018

Clinical Outcomes of Sirolimus-Eluting Bioresorbable Peripheral Scaffold System in Subjects with Critical Limb Ischemia Disease due to De Novo Lesions (Meril)

Presenter: George L Adams, Tony Das, Gireesh Warwadekar

September 21, 2018

Advertisement

RESET: Seven-Year Follow-up From a Randomized Trial of Sirolimus-Eluting vs Everolimus-Eluting Stents in Patients With Coronary Artery Disease

TALENT: Indian-Made Supraflex DES Stands Up Well Against Xience in All-Comers

CORRECTION: Polymer-Free BioFreedom Stent Faces Off Against Orsiro

TCT 2018, Day One: ‘Back to the Future’ With Stents, Stents, and More Stents

TCT-91: Ultrathin Bioresorbable Polymer Sirolimus-Eluting Stents versus Thin Durable Polymer Everolimus-Eluting Stents in Patients Undergoing Coronary Revascularization (BIOFLOW V): Acute Coronary Syndrome Subgroup Analysis

TCT-90: Clinical Outcomes Three Year After Revascularization With a Biodegradable Polymer Ultra-thin Strut Sirolimus-Eluting Stent and a Biodegradable Polymer Biolimus-eluting Stent. From the SORT OUT VII Trial

TCT-197: Early Vascular Healing After Implantation of a Biolimus-Coated BioFreedom Stent or a Sirolimus Eluting Orsiro Stent in Patients with ST-segment Elevation Myocardial Infarction

TCT-64: Two-Year Clinical and Imaging Outcomes of Thin Strut Sirolimus-Eluting Bioresorbable Vascular Scaffolds in De Novo Coronary Artery Lesions: The MeRes-1 Trial

Clinical Outcomes of Sirolimus-Eluting Bioresorbable Peripheral Scaffold System in Subjects with Critical Limb Ischemia Disease due to De Novo Lesions (Meril)

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content